positive data from a Japan-based Phase 3 clinical trial evaluating lead candidate topical sofpironium bromide gel, 5% in patients with primary axillary hyperhidrosis (excessive sweating on the hands, feet and underarms).
53.9% of treated patients achieved at least a 50% reduction in gravimetric sweat production and improved to a score of 1 or 2 in a scale called HDSS at the end of treatment, compared to 36.4% for vehicle
Kaken has filed a marketing application in Japan. It also has development and commercialization rights in Korea, China and certain other countries in Asia.
seekingalpha.com/new...ve-data-on-lead-drug
53.9% of treated patients achieved at least a 50% reduction in gravimetric sweat production and improved to a score of 1 or 2 in a scale called HDSS at the end of treatment, compared to 36.4% for vehicle
Kaken has filed a marketing application in Japan. It also has development and commercialization rights in Korea, China and certain other countries in Asia.
seekingalpha.com/new...ve-data-on-lead-drug